These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20603657)

  • 41. Approval times for new drugs: does the source of funding for FDA staff matter?
    Carpenter D; Chernew M; Smith DG; Fendrick AM
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-618-24. PubMed ID: 15506165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDA's biomedical research program.
    Kelsey FO
    J Parenter Drug Assoc; 1980; 34(2):134-8. PubMed ID: 6989974
    [No Abstract]   [Full Text] [Related]  

  • 43. To market, to market. The nuts and bolts of prescription drug approval.
    Peterson AM
    Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
    [No Abstract]   [Full Text] [Related]  

  • 44. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
    Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs.
    Rosenfeldt H; Kropp T; Benson K; Ricci MS; McGuinn WD; Verbois SL
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):125-33. PubMed ID: 20045015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The FDA takes action against unapproved drugs.
    Meadows M
    FDA Consum; 2007; 41(1):34-5. PubMed ID: 17342837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new history and discussion of 180-day exclusivity.
    Korn DE; Lietzan E; Scott SW
    Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
    Zineh I; Pacanowski MA
    Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Dec; 64(232):67720-63. PubMed ID: 11010665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of the patent and trademark office under 35 U.S.C. section 156.
    Tyson KL
    Food Drug Law J; 1999; 54(2):205-9. PubMed ID: 11758574
    [No Abstract]   [Full Text] [Related]  

  • 52. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
    Cowden AL; Katz KA
    Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New drug and antibiotic regulations--FDA. Proposed rule.
    Fed Regist; 1982 Oct; 47(202):46622-66. PubMed ID: 10262075
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Black box warnings: what do they mean to pharmacists and patients.
    Martin CM; Borgelt L
    Consult Pharm; 2012 Jul; 27(7):482-92. PubMed ID: 22910129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDA's Bioresearch Monitoring Program.
    Kelsey FO
    Methods Find Exp Clin Pharmacol; 1982; 4(7):503-8. PubMed ID: 7169836
    [No Abstract]   [Full Text] [Related]  

  • 58. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.